Evaxion Biotech A/S (EVAX) Stock Analysis

What Evaxion Biotech A/S does

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

Key metrics

ETFs linked to EVAX

Broad-market and Healthcare sector ETFs an investor holding Evaxion Biotech A/S is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EVAX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Evaxion Biotech A/S?

Evaxion Biotech A/S trades under the ticker EVAX on NASDAQ.

Which exchange is EVAX listed on?

EVAX is listed on NASDAQ.

What sector does Evaxion Biotech A/S operate in?

Evaxion Biotech A/S is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze EVAX in a portfolio?

PortView shows EVAX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.